登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TRAIL R2】

TRAIL R2信息

英文名称:Tumor necrosis factor receptor superfamily member 10B
中文名称:肿瘤坏死因子受体超家族成员10B
靶点别称:Tumor necrosis factor receptor superfamily member 10B,CD262,DR5,KILLER,TRAILR2,Death receptor 5,TRAIL-R2,UNQ160/PRO186,TNFRSF10B,TNF Receptor Superfamily Member 10b,TNF-Related Apoptosis-Inducing Ligand Receptor 2,TRICK2,ZTNFR9,P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer),Tumor Necrosis Factor Receptor-Like Protein ZTNFR9,Death Domain Containing Receptor For TRAIL/Apo-2L,Apoptosis Inducing Protein TRICK2A/2B,Apoptosis Inducing Receptor TRAIL-R2,Cytotoxic TRAIL Receptor-2,Fas-Li
上市药物数量:0
临床药物数量:11
最高研发阶段:申请上市

TRAIL R2 分子别名

TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB

TRAIL R2 分子背景

Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain. TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

TRAIL R2 前沿进展

TRAIL R2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Oba-01 Oba-01; Oba01 临床一期 烟台市和元艾迪斯生物医药科技有限公司 非小细胞肺癌 详情
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) 临床三期 深圳未名新鹏生物医药有限公司 肿瘤 详情
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) CTB-006 临床一期 北京同为时代生物技术有限公司, 深圳龙瑞药业有限公司 实体瘤 详情
FAP-DR5 RG-7386; RO-6874813 Millennium Pharmaceuticals Inc, 罗氏 详情
TAS-266 TAS-266 诺华制药, Ablynx 详情
IGM-8444 Igm Biosciences Inc 详情
DS-8273 DS-8273; DS-8273a 第一三共株式会社 详情
Conatumumab AMG-655 安进 详情
BI-905711 BI-905711 临床一期 Boehringer Ingelheim Gmbh 胃肠道癌症 详情
Dulanermin AMG-951; PRO-1762 安进 详情
Drozitumab R-7425; RG-7425; PRO-95780 基因泰克 详情
Tigatuzumab TRA-8; CS-1008; IgG1-kappa 第一三共株式会社, 阿拉巴马大学伯明翰分校 详情
Benufutamab iDD-004; GEN-1029; Hx-DR5-01; Hx-DR5-05 Idd Biotech 详情
Dulanermin (Shanghai GeBaiDe) 临床三期 上海歌佰德生物技术有限公司 非小细胞肺癌 详情
Rilunermin alfa SCB-313 (TRAIL-Trimer) 临床一期 四川三叶草生物制药有限公司 胸水, 腹水, 腹膜癌, 恶性胸腔积液 详情
INBRX-109 JCT-205; INBRX-109 临床一期 Inhibrx 腺癌 详情
Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio) 临床二期 深圳市德和生物科技有限公司 食道癌, 胃癌, 胶质瘤, 肝细胞癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定